- Home
- EYEN vs BOLD Comparison
EYEN vs BOLD Comparison
Compare EYEN & BOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EYEN
- BOLD
- Stock Information
- Founded
- EYEN 2014
- BOLD 2018
- Country
- EYEN United States
- BOLD United States
- Employees
- EYEN N/A
- BOLD N/A
- Industry
- EYEN Biotechnology: Pharmaceutical Preparations
- BOLD
- Sector
- EYEN Health Care
- BOLD
- Exchange
- EYEN Nasdaq
- BOLD Nasdaq
- Market Cap
- EYEN 38.2M
- BOLD 81.0M
- IPO Year
- EYEN 2018
- BOLD 2024
- Fundamental
- Price
- EYEN $0.55
- BOLD $2.95
- Analyst Decision
- EYEN Strong Buy
- BOLD Strong Buy
- Analyst Count
- EYEN 2
- BOLD 3
- Target Price
- EYEN $12.00
- BOLD $23.00
- AVG Volume (30 Days)
- EYEN 879.0K
- BOLD 57.8K
- Earning Date
- EYEN 11-11-2024
- BOLD 11-11-2024
- Dividend Yield
- EYEN N/A
- BOLD N/A
- EPS Growth
- EYEN N/A
- BOLD N/A
- EPS
- EYEN N/A
- BOLD N/A
- Revenue
- EYEN $31,405.00
- BOLD N/A
- Revenue This Year
- EYEN $50,309.30
- BOLD N/A
- Revenue Next Year
- EYEN $421.63
- BOLD N/A
- P/E Ratio
- EYEN N/A
- BOLD N/A
- Revenue Growth
- EYEN N/A
- BOLD N/A
- 52 Week Low
- EYEN $0.37
- BOLD $2.82
- 52 Week High
- EYEN $2.57
- BOLD $15.24
- Technical
- Relative Strength Index (RSI)
- EYEN 52.60
- BOLD N/A
- Support Level
- EYEN $0.52
- BOLD N/A
- Resistance Level
- EYEN $0.59
- BOLD N/A
- Average True Range (ATR)
- EYEN 0.05
- BOLD 0.00
- MACD
- EYEN 0.01
- BOLD 0.00
- Stochastic Oscillator
- EYEN 66.45
- BOLD 0.00
About EYEN Eyenovia Inc.
Eyenovia Inc is a clinical stage ophthalmic company developing a pipeline of therapeutics based on its propriety array print (MAP) platform technology. It aims to achieve clinical microdosing of next-generation formulations of novel and existing ophthalmic pharmaceutical agents using its high-precision targeted ocular delivery system, branded the Opejet, which has the potential to replace conventional eye dropper delivery and improve safety, tolerability, patient compliance and topical delivery success for ophthalmic eye treatments. Using its proprietary delivery technology, Eyenovia is developing the next generation of smart ophthalmic therapies which target new indications or new combinations.
About BOLD Boundless Bio Inc. Common Stock
Boundless Bio Inc is a clinical-stage oncology company. It is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the significant unmet need in patients with oncogene amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in more than 14% of cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.